Loading
12 standard-of-care settings across 4 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers | Risk group |
|---|---|---|
| Early / localised | 3 | 1 |
| Advanced, first line | 3 | · |
| Third line and beyond | 1 | · |
| Other settings | 4 | · |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Localised STS | Wide excision + radiation; neoadjuvant chemotherapy for high-risk. | NCCN Guidelines: Soft Tissue Sarcoma | 93 | |
| All comers | Localised extremity/trunk soft-tissue sarcoma, low grade | Wide resection (limb-salvage) ± radiotherapy for margins or size >5 cm; observation thereafter. | NCCN · Category 1 (surgery ± RT) | 93 | |
| All comers | GIST, localised | Resection; adjuvant imatinib 3 years for high risk (SSGXVIII), longer under study; none for PDGFRA D842V or SDH-deficient (imatinib-insensitive). | NCCN · Category 1 (imatinib 3 years, high-risk)ESMO-MCBS · A | 78 | |
| Risk group | Localised high-risk soft-tissue sarcoma (grade 3, >5 cm, deep) | Neoadjuvant anthracycline-ifosfamide × 3 (ISG-STS 1001) ± preoperative radiotherapy, then wide resection; regional hyperthermia with chemotherapy where available (EORTC 62961). | NCCN · Category 2A (neoadjuvant chemotherapy for h…ESMO-MCBS · A (ISG-STS 1001) | 93 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Advanced | Doxorubicin ± ifosfamide; subtype-directed: imatinib, afami-cel, larotrectinib (tazemetostat was withdrawn in March 2026). | NCCN Guidelines: Soft Tissue Sarcoma | 78 | |
| All comers | Advanced soft-tissue sarcoma, first line | Doxorubicin 75 mg/m2 (single agent) or doxorubicin-ifosfamide for symptomatic/rapid disease (EORTC 62012: PFS but not OS benefit); histotype exceptions: trabectedin or gemcitabine-docetaxel for leiomyosarcoma, paclitaxel for angiosarcoma. Adding olaratumab to doxorubicin gave no survival benefit (ANNOUNCE). | NCCN · Category 1 (anthracycline-based) | 81 | |
| All comers | GIST, advanced | Imatinib 400 mg (800 mg for exon 9) → sunitinib → regorafenib → ripretinib (INVICTUS); avapritinib for PDGFRA D842V; ctDNA KIT genotyping to choose ripretinib vs sunitinib second line (INSIGHT); surgery for oligoprogression. | NCCN · Category 1 sequence | 78 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Advanced soft-tissue sarcoma, later lines | Trabectedin (L-sarcomas), eribulin (liposarcoma), pazopanib (non-adipocytic), gemcitabine-docetaxel, dacarbazine; pembrolizumab for alveolar soft-part sarcoma or UPS; larotrectinib for NTRK fusion; afami-cel or lete-cel for MAGE-A4/NY-ESO-1+ synovial sarcoma and MRCLS. | NCCN · Category 2A | 98 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Osteosarcoma | Neoadjuvant MAP (methotrexate, doxorubicin, cisplatin) → limb-salvage resection → adjuvant MAP; no benefit from adding ifosfamide-etoposide or interferon (EURAMOS-1); metastatic/relapsed: surgery of lung metastases, regorafenib/cabozantinib. | 80 | ||
| All comers | Ewing sarcoma | Interval-compressed VDC/IE (INT-0091, AEWS0031, Euro Ewing 2012) with surgery and/or radiotherapy for local control; high-dose busulfan-melphalan for selected high-risk (Euro-EWING 99 R2); relapse: irinotecan-temozolomide, cabozantinib, trials. | 80 | ||
| All comers | Desmoid tumour | Active surveillance first (many regress); nirogacestat (DeFi) for progressing symptomatic disease; sorafenib alternative; surgery only for select sites; cryoablation for extra-abdominal tumours. | NCCN · Category 1 (nirogacestat) | 77 | |
| All comers | Tenosynovial giant cell tumour | Surgery for localised disease; vimseltinib (MOTION) or pexidartinib (REMS for hepatotoxicity) for diffuse disease not amenable to surgery. | NCCN · Category 2A | 74 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.